There are ongoing studies of third-generation EGFR TKI osimertinib in combination with JAK1 inhibitor itacitinib (NCT03450330 and NCT02917993) in EGFR TKI-resistant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.